Simultaneous technetium-99m MIBI angiography and myocardial perfusion imaging

Area of Science:

• Nuclear Cardiology
• Cardiovascular Imaging
• Radiopharmaceuticals

Background:

• Resting first-pass radionuclide angiography (FPRNA) is a key diagnostic tool.
• Evaluating myocardial perfusion and cardiac function simultaneously is clinically important.

Purpose of the Study:

• To assess the efficacy of technetium-99m MIBI (methoxyisobutyl isonitrile) as a myocardial perfusion agent for simultaneous evaluation of cardiac function and perfusion at rest.
• To compare MIBI-based FPRNA with technetium-99m diethylenetriamine pentaacetic acid (DTPA) FPRNA and contrast ventriculography.

Main Methods:

• Resting first-pass radionuclide angiography (FPRNA) was performed using technetium-99m MIBI.
• MIBI-derived left and right ventricular ejection fractions were compared with DTPA-derived values.
• MIBI-derived segmental wall motion was compared with contrast ventriculography.
• MIBI segmental wall motion and perfusion scores were correlated in patients with myocardial infarction.

Main Results:

• Significant correlations were found between MIBI and DTPA for both left (r=0.93) and right (r=0.92) ventricular ejection fractions (p<0.001).
• High correlation (p<0.001) and qualitative agreement (38/52 segments) were observed between MIBI-derived segmental wall motion and contrast ventriculography.
• Significant correlation (p<0.001) existed between MIBI segmental wall motion and perfusion scores in myocardial infarction patients.
• All 18 diseased segments in patients with prior myocardial infarction were correctly identified by MIBI.

Conclusions:

• Technetium-99m MIBI is a valuable radiopharmaceutical for the simultaneous assessment of cardiac function and myocardial perfusion at rest.
• MIBI demonstrates high accuracy and reliability when compared to established imaging modalities.
• This agent holds promise for comprehensive cardiac evaluation in a single study.